4.4 Article

Molecular mechanisms associated with leukemic transformation of MPL-mutant myeloproliferative neoplasms

Journal

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL
Volume 95, Issue 12, Pages 2153-2156

Publisher

FERRATA STORTI FOUNDATION
DOI: 10.3324/haematol.2010.029306

Keywords

MPL; JAK2; TP53; TET2; myeloproliferative neoplasm; acute myeloid leukemia; essential thrombocythemia; primary myelofibrosis; hydroxycarbamide

Categories

Funding

  1. UK Medical Research Council
  2. Leukaemia and Lymphoma Research
  3. Kay Kendal Leukaemia Fund
  4. NIHR Cambridge Biomedical Research Centre
  5. Leukemia and Lymphoma Society of America
  6. MIUR
  7. Cancer Research UK [8961] Funding Source: researchfish

Ask authors/readers for more resources

Somatic activating mutations in MPL, the thrombopoietin receptor, occur in the myeloproliferative neoplasms, although virtually nothing is known about their role in evolution to acute myeloid leukemia. In this study, the MPL T487A mutation, identified in de novo acute myeloid leukemia, was not detected in 172 patients with a myeloproliferative neoplasm. In patients with a prior MPL W515L-mutant myeloproliferative neoplasm, leukemic transformation was accompanied by MPL-mutant leukemic blasts, was seen in the absence of prior cytoreductive therapy and often involved loss of wild-type MPL by mitotic recombination. Moreover, clonal analysis of progenitor colonies at the time of leukemic transformation revealed the presence of multiple genetically distinct but phylogenetically-related clones bearing different TP53 mutations, implying a mutator-phenotype and indicating that leukemic transformation may be preceded by the parallel expansion of diverse hematopoietic clones.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available